GRACE :: Lung Cancer

progression

Understanding Acquired Resistance in ALK+ Lung Cancer

Share

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments – and why some do better than expected. February 2014


Treating Brain Mets in ALK+ Lung Cancer

Share

For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014


ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori

Share

New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the “Download” button above. Get the latest QuickTime Player.)


ALK Positive Lung Cancer Forum 2014: Xalkori

Share

Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval, as well as the limitations and side effects of the drug.

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the “Download” button above. Get the latest QuickTime Player.)


How do you approach acquired resistance to a targeted therapy in lung cancer? Follow the algorithm!

Share

The question of how best to manage “acquired resistance” to a targeted therapy like an EGFR or ALK inhibitor in someone who has had a great response for a long time can be complicated and really doesn’t have a best answer.  However, other doctors and many patients here and in the brick and mortar world ask me about how I approach it, and I’ve got some real opinions about it.  I’ll qualify my further comments by saying that my own views have evolved over the years as we’ve gained more information as we get more clinical data and practical experience. I’ll also say that no expert can be dogmatic that theirs is the best approach.  Still, I’m pretty sure I’m right, and I realized that this strategy is remarkably similar to my approach to a slow-growing cancer like bronchioloalveolar carcinoma of the lung — so I adapted that algorithm to illustrate my actual decision-making process for a patient who comes to me in my own clinic, whether someone I’ve been following for years or as a new second opinion because of a change.

Acquired resistance Algorithm CG

I’ll add that I don’t specify WHAT systemic therapy to add when it appears that it’s time to add a systemic therapy to the targeted therapy on which someone is slowly progressing or replace the targeted therapy with a new systemic therapy.  There is no right answer to this question, though I feel that I’d approach this like someone with previously untreated advanced NSCLC who doesn’t have a driver mutation: use the doublet chemo +/- Avastin (bevacizumab) you would otherwise start someone on as first line treatment.  However, a trial of a novel targeted therapy, perhaps specifically for patients with acquired resistance to the agent the person is on, would be extremely appealing as well. I hope and expect that we’ll learn more about this.

Also, please note my comment at the bottom about a repeat biopsy of the progressing lesion(s).  I have mixed feelings about this.  Though I definitely think this is and will continue to be a driver of our better understanding of the biology of lung cancer in general and acquired resistance specifically, I need to point out that most people won’t have an “actionable” result that leads to a practical improvement in our ability to manage the cancer or offer an effective alternative treatment — particularly if the person isn’t at a very large academic center with many trials of novel therapies.  In addition, insurers may not pay for this intervention that isn’t part of an evidence-based standard of care right now, so there’s a change that a repeat biopsy could incur significant costs along with some small risks from the procedure itself.

Final bonus: this algorithm is also pretty close to how I’d approach someone with slow progression on nearly any other systemic therapy for other cancers.  The key is the clinical significance, the pace of progression, and whether it’s very limited or diffuse.

Continue reading


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Website Rebuild

Share

Acquired Resistance Forum Videos

 

Watch ALK+ Lung Cancer Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

PeerView Press - Curriculum-Based Learning Activities